Role of estrogen in diastolic dysfunction

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 306, Issue 5, 2014, Pages

  Zhao, Zhuo ^a,b   Wang, Hao ^b   Jessup, Jewell A ^b   Lindsey, Sarah H ^c   Chappell, Mark C ^b   Groban, Leanne ^b  

^a SHANDONG UNIVERSITY   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diastolic dysfunction; Doppler echocardiography; Estrogen; G protein coupled receptor 30; MRen2; Sex differences

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSINOGEN; CHYMASE; COLLAGEN TYPE 1; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLAVINE ADENINE NUCLEOTIDE; G PROTEIN COUPLED RECEPTOR 30; GESTAGEN; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE SYNTHASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SUPEROXIDE; TROPONIN C; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE;

AORTA CONSTRICTION; BONE DENSITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CORRELATION ANALYSIS; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DOPPLER ECHOCARDIOGRAPHY; ESTROGEN THERAPY; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; INSULIN RESISTANCE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHENOTYPE; PLASMA RENIN ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; REVIEW; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; AGE; ANIMAL; DIASTOLE; DISEASE MODEL; DRUG EFFECT; ECHOGRAPHY; FEMALE; G PROTEIN-COUPLED RECEPTOR 30; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; MREN2; PATHOPHYSIOLOGY; RISK FACTOR; SEX DIFFERENCES; SIGNAL TRANSDUCTION;

DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; ESTROGEN; G PROTEIN-COUPLED RECEPTOR 30; MREN2; SEX DIFFERENCES;

AGE FACTORS; ANIMALS; DIASTOLE; DISEASE MODELS, ANIMAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MYOCARDIUM; NITRIC OXIDE SYNTHASE; POSTMENOPAUSE; REACTIVE OXYGEN SPECIES; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SEX FACTORS; SIGNAL TRANSDUCTION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84899097751     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00859.2013     Document Type: Review

References (167)

1. Ahmed A. Association of diastolic dysfunction and outcomes in ambulatory older adults with chronic heart failure. J Gerontol A Biol Sci Med Sci 60: 1339-1344, 2005.
2. Aijaz B, Ammar KA, Lopez-Jimenez F, Redfield MM, Jacobsen SJ, Rodeheffer RJ. Abnormal cardiac structure and function in the metabolic syndrome: a population-based study. Mayo Clin Proc 83: 1350-1357, 2008.
3. Ashraf MS, Vongpatanasin W. Estrogen and hypertension. Curr Hypertens Rep 8: 368-376, 2006.
4. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 37: 1042-1048, 2001.
5. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 351: 1097-1105, 2004.
6. Baiardi G, Macova M, Armando I, Ando H, Tyurmin D, Saavedra JM. Estrogen upregulates renal angiotensin II AT1 and AT2 receptors in the rat. Regul Pept 124: 7-17, 2005.
7. Bopassa JC, Eghbali M, Toro L, Stefani E. A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 298: H16-H23, 2010.
8. Borbély A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. Circulation 111: 774-781, 2005.
9. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 69: 107-115, 1991.
10. Brosnihan KB, Li P, Ganten D, Ferrario CM. Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS. Am J Physiol Regul Integr Comp Physiol 273: R1908-R1915, 1997.
11. Bybee KA, Stevens TL. Matters of the heart: cardiovascular disease in U.S. women. Mo Med 110: 65-70, 2013.
12. Camper-Kirby D, Welch S, Walker A, Shiraishi I, Setchell KD, Schaefer E, Kajstura J, Anversa P, Sussman MA. Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res 88: 1020-1027, 2001.
13. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45: 607-617, 1997.
14. Chappell MC, Gallagher PE, Averill DB, Ferrario CM, Brosnihan KB. Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat. Hypertension 42: 781-786, 2003.
15. Chappell MC, Modrall JG, Diz DI, Ferrario CM. Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contrib Nephrol 143: 77-89, 2004.
16. Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 50: 596-599, 2007.
17. Chappell MC, Westwood BM, Yamaleyeva LM. Differential effects of sex steroids in young and aged female mRen2. Lewis rats: a model of estrogen and salt-sensitive hypertension. Gend Med 5, Suppl A: S65-S75, 2008.
18. Chen CH, Nakayama M, Nevo E, Fetics BJ, Maughan WL, Kass DA. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 32: 1221-1227, 1998.
19. Cheng CP, Suzuki M, Ohte N, Ohno M, Wang ZM, Little WC. Altered ventricular and myocyte response to angiotensin II in pacinginduced heart failure. Circ Res 78: 880-892, 1996.
20. Chiao YA, Ramirez TA, Zamilpa R, Okoronkwo SM, Dai Q, Zhang J, Jin YF, Lindsey ML. Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res 96: 444-455, 2012.
21. Clarkson TB, Meléndez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 20: 342-353, 2013.
22. Clerico A, Fontana M, Vittorini S, Emdin M. The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: proposal for a working hypothesis. Clin Chim Acta 405: 1-7, 2009.
23. Consoli C, Gatta L, Iellamo F, Molinari F, Rosano GM, Marlier LN. Severity of left ventricular dysfunction in heart failure patients affects the degree of serum-induced cardiomyocyte apoptosis. Importance of inflammatory response and metabolism. Int J Cardiol 167: 2859-2866, 2013.
24. Correa de Sa DD, Hodge DO, Slusser JP, Redfield MM, Simari RD, Burnett JC, Chen HH. Progression of preclinical diastolic dysfunction to the development of symptoms. Heart 96: 528-532, 2010.
25. Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 16: 853-862, 1998.
26. Deschamps AM, Murphy E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 297: H1806-H1813, 2009.
27. De Simone G, Devereux RB, Chinali M, Roman MJ, Barac A, Panza JA, Lee ET, Howard BV. Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study. J Hypertens 29: 1431-1438, 2011.
28. Douglas PS, Katz SE, Weinberg EO, Chen MH, Bishop SP, Lorell BH. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 32: 1118-1125, 1998.
29. Edelmann F, Wachter R, Pieske B. Aldosterone inhibition in patients with heart failure with preserved ejection fraction-reply. JAMA 310: 205-207, 2013.
30. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52: 428-434, 2008.
31. Feldman DE, Ducharme A, Giannetti N, Frenette M, Michel C, Grondin F, Sheppard R, Lauriers JD, Behlouli H, Pilote L. Severity at entry to specialized heart failure clinics: discrepancies between healthrelated quality of life and function in men and women. Can J Cardiol 27: 382-387, 2011.
32. Filice E, Recchia AG, Pellegrino D, Angelone T, Maggiolini M, Cerra MC. A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17β-estradiol in the male rat. J Physiol Pharmacol 60: 3-10, 2009.
33. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14: 1649-1660, 2000.
34. Filardo EJ, Quinn JA, Frackelton AR, Bland KI. Estrogen activation via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16: 70-84, 2002.
35. Friedman MM. Gender differences in the health related quality of life of older adults with heart failure. Heart Lung 32: 320-327, 2003.
36. Frye JB, Lukefahr AL, Wright LE, Marion SL, Hoyer PB, Funk JL. Modeling perimenopause in Sprague-Dawley rats by chemical manipulation of the transition to ovarian failure. Comp Med 62: 193-202, 2012.
37. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273: 1450-1456, 1995.
38. Ghali JK, Lindenfeld J. Sex differences in response to chronic heart failure therapies. Expert Rev Cardiovasc Ther 6: 555-565, 2008.
39. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35: 1628-1637, 2000.
40. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288: 49-57, 2002.
41. Groban L, Yamaleyeva LM, Westwood BM, Houle TT, Lin M, Kitzman DW, Chappell MC. Progressive diastolic dysfunction in the female mRen(2). Lewis rat: influence of salt and ovarian hormones. J Gerontol A Biol Sci Med Sci 63: 3-11, 2008.
42. Groban L, Wang H, Machado F, Trask AJ, Kritchevsky SB, Ferrario CM, Diz DI. Low glial angiotensinogen improves body habitus, diastolic function, and exercise tolerance in aging male rats. Cardiovasc Endocrinol 1: 49-58, 2012.
43. Groeschel M, Braam B. Connecting chronic and recurrent stress to vascular dysfunction: no relaxed role for the renin-angiotensin system. Am J Physiol Renal Physiol 300: F1-F10, 2011.
44. Grohé C, Kahlert S, Löbbert K, Stimpel M, Karas RH, Vetter H, Neyses L. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett 416: 107-112, 1997.
45. Haas E, Bhattacharya I, Brailoiu E, Damjanovíc M, Brailoiu GC, Gao X, Mueller-Guerre L, Marjon NA, Gut A, Minotti R, Meyer MR, Amann K, Ammann E, Perez-Dominguez A, Genoni M, Clegg DJ, Dun NJ, Resta TC, Prossnitz ER, Barton M. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 104: 288-291, 2009.
46. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction/clinical perspective. Circ Heart Fail 4: 324-331, 2011.
47. Habibi J, DeMarco VG, Ma L, Pulakat L, Rainey WE, Whaley-Connell AT, Sowers JR. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol 300: H1484-H1491, 2011.
48. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 8: 3-12, 2005.
49. Hayes SN, Taler SJ. Hypertension in women: current understanding of gender differences. Mayo Clin Proc 73: 157-165, 1998.
50. Henderson BC, Tyagi SC. Oxidative mechanism and homeostasis of proteinase/antiproteinase in congestive heart failure. J Mol Cell Cardiol 41: 959-962, 2006.
51. Henderson BC, Tyagi N, Ovechkin A, Kartha GK, Moshal KS, Tyagi SC. Oxidative remodeling in pressure overload induced chronic heart failure. Eur J Heart Fail 9: 450-457, 2007.
52. Heo S, Moser DK, Widener J. Gender differences in the effects of physical and emotional symptoms on health-related quality of life in patients with heart failure. Eur J Cardiovasc Nurs 6: 146-152, 2007.
53. Hodis HN, Mack WJ. A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age-and time-dependent. Brain Res 1379: 244-252, 2011.
54. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 15: 217-228, 2012.
55. Hodis HN, Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 1: comparison of therapeutic efficacy. J Am Geriatr Soc 61: 1005-1010, 2013.
56. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43: 317-327, 2004.
57. Holycross BJ, Summers BM, Dunn RB, McCune SA. Plasma renin activity in heart failure-prone SHHF/Mcc-facp rats. Am J Physiol Heart Circ Physiol 273: H228-H233, 1997.
58. Hong M, Yan Q, Tao B, Boersma A, Han KK, Vantyghem MC, Racadot A, Lefebvre J. Estradiol, progesterone and testosterone exposures affect the atrial natriuretic peptide gene expression in vivo in rats. Biol Chem Hoppe Seyler 373: 213-218, 1992.
59. Horn MA, Graham HK, Richards MA, Clarke JD, Greensmith DJ, Briston SJ, Hall MC, Dibb KM, Trafford AW. Age-related divergent remodeling of the cardiac extracellular matrix in heart failure: collagen accumulation in the young and loss in the aged. J Mol Cell Cardiol 53: 82-90, 2012.
60. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613, 1998.
61. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 291: H2166-H2172, 2006.
62. Jessup JA, Lindsey SH, Wang H, Chappell MC, Groban L. Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2. Lewis rats. PLOS ONE 5: e15433, 2010.
63. Jessup JA, Zhang L, Chen AF, Presley TD, Kim-Shapiro DB, Chappell MC, Wang H, Groban L. Neuronal nitric oxide synthase inhibition improves diastolic function and reduces oxidative stress in ovariectomized mRen2. Lewis rats. Menopause 18: 698-708, 2011.
64. Jessup JA, Zhang L, Presley TD, Kim-Shapiro DB, Wang H, Chen AF, Groban L. Tetrahydrobiopterin restores diastolic function and attenuates superoxide production in ovariectomized mRen2. Lewis rats. Endocrinology 152: 2428-2436, 2011.
65. Jessup JA, Wang H, MacNamara LM, Presley TD, Kim-Shapiro DB, Zhang L, Chen AF, Groban L. Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2. Lewis rats. Menopause 20: 860-868, 2013.
66. Jessup M, Brozena S. Heart failure. N Engl J Med 348: 2007-2018, 2003.
67. Jiménez-Navarro MF, Ramirez-Marrero MA, Anguita-Sánchez M, Castillo JC; BADAPIC Investigators. Influence of gender on long-term prognosis of patients with chronic heart failure seen in heart failure clinics. Clin Cardiol 33: E13-E18, 2010.
68. Kang S, Liu Y, Sun D, Zhou C, Liu A, Xu C, Hao Y, Li D, Yan C, Sun H. Chronic activation of the G protein-coupled receptor 30 with agonist G-1 attenuates heart failure. PLOS ONE 7: e48185, 2012.
69. Karjalainen AH, Ruskoaho H, Vuolteenaho O, Heikkinen JE, Bäckström AC, Savolainen MJ, Kesäniemi YA. Effects of estrogen replacement therapy on natriuretic peptides and blood pressure. Maturitas 47: 201-208, 2004.
70. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 94: 1533-1542, 2004.
71. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 107: 714-720, 2003.
72. Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev 7: 17-27, 2002.
73. Kitzman DW, Groban L. Exercise intolerance. Cardiol Clin 29: 461-477, 2011.
74. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther 135: 54-70, 2012.
75. 2+ exchange in the heart from ovariectomized rats: role of protein kinase A. Am J Physiol Cell Physiol 292: C1625-C1635, 2007.
76. Lacombe VA, Viatchenko-Karpinski S, Terentyev D, Sridhar A, Emani S, Bonagura JD, Feldman DS, Györke S, Carnes CA. Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes. Am J Physiol Regul Integr Comp Physiol 293: R1787-R1797, 2007.
77. Lam CS, Cheng S, Choong K, Larson MG, Murabito JM, Newton-Cheh C, Bhasin S, McCabe EL, Miller KK, Redfield MM, Vasan RS, Coviello AD, Wang TJ. Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol 58: 618-626, 2011.
78. Lam KK, Lee YM, Hsiao G, Chen SY, Yen MH. Estrogen therapy replenishes vascular tetrahydrobiopterin and reduces oxidative stress in ovariectomized rats. Menopause 13: 294-302, 2006.
79. Levick SP, Meléndez GC, Plante E, McLarty JL, Brower GL, Janicki JS. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res 89: 12-19, 2011.
80. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2. Lewis rats. Endocrinology 150: 3753-3758, 2009.
81. Lindsey SH, Carver KA, Prossnitz ER, Chappell MC. Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2. Lewis female rat. J Cardiovasc Pharmacol 57: 598-603, 2011.
82. Lindsey SH, da Silva AS, Silva MS, Chappell MC. Reduced vasorelaxation to estradiol and G-1 in aged female and adult male rats is associated with GPR30 downregulation. Am J Physiol Endocrinol Metab 305: E113-E118, 2013.
83. Linsdey SH, Liu L, Chappell MC. Vasodilation by GPER in mesenteric arteries involves both endothelial nitric oxide and smooth muscle cAMP signaling. Steroids; http://dx.doi.org/10.1016/j.steroids.2013.10.017.
84. Lipman RD, Chrisp CE, Hazzard DG, Bronson RT. Pathologic characterization of brown Norway, brown Norway × Fischer 344, and Fischer 344 × brown Norway rats with relation to age. J Gerontol A Biol Sci Med Sci 51: B54-B59, 1996.
85. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y; American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119: e21-e181, 2009.
86. López-Rivera E, Lizarbe TR, Martínez-Moreno M, López-Novoa JM, Rodríguez-Barbero A, Rodrigo J, Fernández AP, Alvarez-Barrientos A, Lamas S, Zaragoza C. Matrix metalloproteinase 13 mediates nitric oxide activation of endothelial cell migration. Proc Natl Acad Sci USA 102: 3685-3690, 2005.
87. Maffucci JA, Gore AC. Age-related changes in hormones and their receptors in animal models of female reproductive senescence. In: Handbook of Models for Human Aging, edited by Conn MP. Burlington, MA: Elsevier, 2006, p. 533-552.
88. Manson JE. The Kronos Early Estrogen Prevention Study by Charlotte Barker. Women Health 9: 9-11, 2013.
89. Manrique C, DeMarco VG, Aroor AR, Mugerfeld I, Garro M, Habibi J, Hayden MR, Sowers JR. Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology 154: 3632-3642, 2013.
90. Marques CM, Nascimento FA, Mandarim-de-Lacerda CA, Aguila MB. Exercise training attenuates cardiovascular adverse remodeling in adult ovariectomized spontaneously hypertensive rats. Menopause 13: 87-95, 2006.
91. Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC Jr. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol 302: R292-R299, 2012.
92. Maurer MS, Spevack D, Burkhoff D, Kronzon I. Diastolic dysfunction. Can it be diagnosed by Doppler echocardiography? J Am Coll Cardiol 44: 1543-1549, 2004.
93. Mayer LP, Devine PJ, Dyer CA, Hoyer PB. The follicle-deplete mouse ovary produces androgen. Biol Reprod 71: 130-138, 2004.
94. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int 55: 278-285, 1999.
95. Miyazaki-Akita A, Hayashi T, Ding QF, Shiraishi H, Nomura T, Hattori Y, Iguchi A. 17β-Estradiol antagonizes the down-regulation of endothelial nitric-oxide synthase and GTP cyclohydrolase I by high glucose: relevance to postmenopausal diabetic cardiovascular disease. J Pharmacol Exp Ther 320: 591-598, 2007.
96. Mizutani S, Ishii M, Hattori A, Nomura S, Numaguchi Y, Tsujimoto M, Kobayshi H, Murohara T, Wright JW. New insights into the importance of aminopeptidase A in hypertension. Heart Fail Rev 13: 273-284, 2008.
97. 3-adrenoreceptor. J Mol Cell Cardiol 47: 576-585, 2009.
98. Mori T, Kai H, Kajimoto H, Koga M, Kudo H, Takayama N, Yasuoka S, Anegawa T, Kai M, Imaizumi T. Enhanced cardiac inflammation and fibrosis in ovariectomized hypertensive rats: a possible mechanism of diastolic dysfunction in postmenopausal women. Hypertens Res 34: 496-502, 2011.
99. Murase T, Hattori T, Ohtake M, Nakashima C, Takatsu M, Murohara T, Nagata K. Effects of estrogen on cardiovascular injury in ovariectomized female DahlS. Z-Leprfa/Leprfa rats as a new animal model of metabolic syndrome. Hypertension 59: 694-704, 2012.
100. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13: 745-753, 2002.
101. Nickenig G, Bäumer AT, Grohè C, Kahlert S, Strehlow K, Rosenkranz S, Stäblein A, Beckers F, Smits JF, Daemen MJ, Vetter H, Böhm M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 97: 2197-2201, 1998.
102. Nicklas BJ, Cesari M, Penninx BWJH, Kritchevsky SB, Ding J, Newman A, Kitzman DW, Kanaya AM, Pahor M, Harris TB. Abdominal obesity is an independent risk factor for chronic heart failure in older people. J Am Geriatr Soc 54: 413-420, 2006.
103. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355: 251-259, 2006.
104. Patten RD, Hall-Porter MR. Small animal models of heart failure: development of novel therapies, past and present. Circ Heart Fail 2: 138-144, 2009.
105. Pechenino AS, Lin L, Mbai FN, Lee AR, He XM, Stallone JN, Knowlton AA. Impact of aging vs. estrogen loss on cardiac gene expression: estrogen replacement and inflammation. Physiol Genomics 43: 1065-1073, 2011.
106. Pendergrass KD, Averill DB, Ferrario CM, Diz DI, Chappell MC. Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2. Lewis rat. Am J Physiol Renal Physiol 290: F1497-F1506, 2006.
107. Pendergrass KD, Pirro NT, Westwood BM, Ferrario CM, Brosnihan KB, Chappell MC. Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats. Am J Physiol Heart Circ Physiol 295: H10-H20, 2008.
108. Perticone F, Sciacqua A, Maio R, Perticone M, Laino I, Bruni R, Cello SD, Leone GG, Greco L, Andreozzi F, Sesti G. Renal function predicts cardiovascular outcomes in southern Italian postmenopausal women. Eur J Cardiovasc Prev Rehabil 16: 481-486, 2009.
109. Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, Dávila-Román VG. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 43: 1399-1404, 2004.
110. Peterson LR, Saeed IM, McGill JB, Herrero P, Schechtman KB, Gunawardena R, Recklein CL, Coggan AR, Demoss AJ, Dence CS, Gropler RJ. Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans. Obesity 20: 802-810, 2011.
111. Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 346: 89-90, 1995.
112. Ram R, Mickelsen DM, Theodoropoulos C, Blaxall BC. New approaches in small animal echocardiography: imaging the sounds of silence. Am J Physiol Heart Circ Physiol 301: H1765-H1780, 2011.
113. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age-and gender-related ventricular-vascular stiffening: a communitybased study. Circulation 112: 2254-2262, 2005.
114. Regitz-Zagrosek V, Oertelt-Prigione S, Seeland U, Hetzer R. Sex and gender differences in myocardial hypertrophy and heart failure. Circ J 74: 1265-1273, 2010.
115. Reichelt ME, Mellor KM, Bell JR, Chandramouli C, Headrick JP, Delbridge LM. Sex, sex steroids, and diabetic cardiomyopathy: making the case for experimental focus. Am J Physiol Heart Circ Physiol 305: H779-H792, 2013.
116. Roesch DM, Tian Y, Zheng W, Shi M, Verbalis JG, Sandberg K. Estradiol attenuates angiotensin-induced aldosterone secretion in ovariectomized rats. Endocrinology 141: 4629-4636, 2000.
117. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125: e2-e220, 2012.
118. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
119. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol Heart Circ Physiol 250: H822-H827, 1986.
120. 2+ leak and improves diastolic function in vitro in murine and human non-failing myocardium. Br J Pharmacol 167: 493-504, 2012.
121. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 21: 363-366, 2006.
122. Sanders D, Dudley M, Groban L. Diastolic dysfunction, cardiovascular aging, and the anesthesiologist. Anesthesiol Clin 27: 497-517, 2009.
123. Schulz E, Jansen T, Wenzel P, Daiber A, Münzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 10: 1115-1126, 2008.
124. Schumacher A, Khojeini E, Larson D. ECHO parameters of diastolic dysfunction. Perfusion 23: 291-296, 2008.
125. Schunkert H, Danser AH, Hense HW, Derkx FH, Kürzinger S, Riegger GA. Effects of estrogen replacement therapy on the reninangiotensin system in postmenopausal women. Circulation 95: 39-45, 1997.
126. Serova LI, Maharjan S, Huang A, Sun D, Kaley G, Sabban EL. Response of tyrosine hydroxylase and GTP cyclohydrolase I gene expression to estrogen in brain catecholaminergic regions varies with mode of administration. Brain Res 1015: 1-8, 2004.
127. Serova LI, Maharjan S, Sabban EL. Estrogen modifies stress response of catecholamine biosynthetic enzyme genes and cardiovascular system in ovariectomized female rats. Neuroscience 132: 249-259, 2005.
128. Serova LI, Filipenko M, Schilt N, Veerasirikul M, Sabban EL. Estrogen-triggered activation of GTP cyclohydrolase 1 gene expression: role of estrogen receptor subtypes and interaction with cyclic AMP. Neuroscience 140: 1253-1263, 2006.
129. Shapiro Y, Boaz M, Matas Z, Fux A, Shargorodsky M. The association between the renin-angiotensin-aldosterone system and arterial stiffness in young healthy subjects. Clin Endocrinol (Oxf) 68: 510-512, 2008.
130. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L. Efficacy of angiotensin-converting enzyme inhibitors and β-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41: 1529-1538, 2003.
131. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, Boulden BM, Widder J, Fredd S, Bernstein KE, Wolska BM, Dikalov S, Harrison DG, Dudley SC Jr. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 121: 519-528, 2010.
132. Smith CC, Vedder LC, Nelson AR, Bredemann TM, McMahon LL. Duration of estrogen deprivation, not chronological age, prevents estrogen's ability to enhance hippocampal synaptic physiology. Proc Natl Acad Sci USA 107: 19543-19548, 2010.
133. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380: 1387-1395, 2012.
134. Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens 3: 427-433, 1989.
135. Stein GY, Ben-Gal T, Kremer A, Bental T, Alon D, Korenfeld R, Yedidia I, Porter A, Abramson E, Sagie A, Fuchs S. Gender-related differences in hospitalized heart failure patients. Eur J Heart Fail 15: 734-741, 2013.
136. Stice JP, Eiserich JP, Knowlton AA. Role of aging versus the loss of estrogens in the reduction in vascular function in female rats. Endocrinology 150: 212-219, 2009.
137. Stiles S. Aldo-Antagonist Falls Short but Impresses in Preserved-EF Heart Failure: TOPCAT. (online) http://www.medscape.com/viewarticle/ 814622 [12 December 2013].
138. Stroes E, Hijmering M, van Zandvoort M, Wever R, Rabelink TJ, van Faassen EE. Origin of superoxide production by endothelial nitric oxide synthase. FEBS Lett 438: 161-164, 1998.
139. Sullivan JC. Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Regul Integr Comp Physiol 294: R1220-R1226, 2008.
140. Sweitzer NK, Stevenson LW. Diastolic heart failure: miles to go before we sleep. Am J Med 109: 683-685, 2000.
141. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 115: 1221-1231, 2005.
142. Thomas MD, Fox KF, Coats AJ, Sutton GC. The epidemiological enigma of heart failure with preserved systolic function. Eur J Heart Fail 6: 125-136, 2004.
143. Tyagi SC, Hayden MR. Role of nitric oxide in matrix remodeling in diabetes and heart failure. Heart Fail Rev 8: 23-28, 2003.
144. Vásquez-Vivar J, Kalyanaraman B, Martásek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 95: 9220-9225, 1998.
145. Victor BM, Barron JT. Diastolic heart failure versus diastolic dysfunction: difference in renal function. Clin Cardiol 33: 770-774, 2010.
146. Vogel MW, Slusser JP, Hodge DO, Chen HH. The natural history of preclinical diastolic dysfunction: a population-based study. Circ Heart Fail 5: 144-151, 2012.
147. Voloshenyuk TG, Gardner JD. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females. Am J Physiol Regul Integr Comp Physiol 299: R683-R693, 2010.
148. von Lueder TG, Sangaralingham SJ, Wang BH, Kompa AR, Atar D, Burnett JC Jr, Krum H. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 6: 594-605, 2013.
149. Wang H, Jessup JA, Lin MS, Chagas C, Lindsey SH, Groban L. Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2. Lewis rats. Cardiovasc Res 94: 96-104, 2012.
150. Wang H, Jessup JA, Zhao Z, Da Silva J, Lin M, MacNamara LM, Ahmad S, Chappell MC, Ferrario CM, Groban L. Characterization of the cardiac renin angiotensin system in oophorectomized and estrogenreplete mRen2. Lewis rats. PLOS ONE 8: e76992, 2013.
151. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 15: 264-272, 2000.
152. Weil BR, Manukyan MC, Herrmann JL, Wang Y, Abarbanell AM, Poynter JA, Meldrum DR. Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery 148: 436-443, 2010.
153. Weinberg EO, Thienelt CD, Katz SE, Bartunek J, Tajima M, Rohrbach S, Douglas PS, Lorell BH. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 34: 264-273, 1999.
154. Whaley-Connell A, Habibi J, Rehmer N, Ardhanari S, Hayden MR, Pulakat L, Krueger C, Ferrario CM, DeMarco VG, Sowers JR. Renin inhibition and AT1R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. Metabolism 62: 861-872, 2013.
155. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583-592, 2003.
156. Witteveen CF, Giovanelli J, Kaufman S. Reduction of quinonoid dihydrobiopterin to tetrahydrobiopterin by nitric oxide synthase. J Biol Chem 271: 4143-4147, 1996.
157. Witteveen CF, Giovanelli J, Kaufman S. Reactivity of tetrahydrobiopterin bound to nitric-oxide synthase. J Biol Chem 274: 29755-29762, 1999.
158. Wu Z, Maric C, Roesch DM, Zheng W, Verbalis JG, Sandberg K. Estrogen regulates adrenal angiotensin AT1 receptors by modulating AT1 receptor translation. Endocrinology 144: 3251-3261, 2003.
159. Yamaleyeva LM, Gallagher PE, Vinsant S, Chappell MC. Discoordinate regulation of renal nitric oxide synthase isoforms in ovariectomized mRen2. Lewis rats. Am J Physiol Regul Integr Comp Physiol 292: R819-R826, 2007.
160. Yamaleyeva LM, Pendergrass KD, Pirro NT, Gallagher PE, Groban L, Chappell MG. Ovariectomy is protective against renal injury in the high-salt-fed older mRen2. Lewis rat. Am J Physiol Heart Circ Physiol 293: H2064-H2071, 2007.
161. Yamaleyeva LM, Lindsey SH, Varagic J, Zhang LL, Gallagher PE, Chen AF, Chappell MC. Amelioration of renal injury and oxidative stress by the nNOS inhibitor L-VNIO in the salt-sensitive mRen2. Lewis congenic rat. J Cardiovasc Pharmacol 59: 529-538, 2012.
162. Yanes LL, Romero DG, Iliescu R, Zhang H, Davis D, Reckelhoff JF. Postmenopausal hypertension: role of the renin-angiotensin system. Hypertension 56: 359-363, 2010.
163. Yu X, Ma H, Barman SA, Liu AT, Sellers M, Stallone JN, Prossnitz ER, White RE, Han G. Activation of G protein-coupled estrogen receptor induces endothelium-independent relaxation of coronary artery smooth muscle. Am J Physiol Endocrinol Metab 301: E882-E888, 2011.
164. Yung LM, Wong WT, Tian XY, Leung FP, Yung LH, Chen ZY, Yao X, Lau CW, Huang Y. Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats. PLOS ONE 6: e17437, 2011.
165. Zapater P, Novalbos J, Gallego-Sandín S, Hernández FT, Abad-Santos F. Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers. J Cardiovasc Pharmacol 43: 737-744, 2004.
166. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 105: 1503-1508, 2002.
167. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350: 1953-1959, 2004.